(-0.34%) 5 050.00 points
(-0.16%) 37 932 points
(-0.63%) 17 461 points
(-1.42%) $80.77
(-3.01%) $1.931
(-0.36%) $2 294.60
(-0.07%) $26.64
(-0.40%) $944.40
(0.10%) $0.938
(0.28%) $11.13
(0.07%) $0.801
(0.56%) $93.98
9.04% $ 8.44
Live Chart Being Loaded With Signals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases...
Stats | |
---|---|
Volumen de hoy | 1 479.00 |
Volumen promedio | 1 477.00 |
Capitalización de mercado | 1.79M |
EPS | $0 ( 2023-09-29 ) |
Last Dividend | $0.150 ( 2024-01-19 ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.12 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-21 | Mcbarron Paul | Buy | 1 886 | Common Stock |
2023-12-21 | Mcbarron Paul | Buy | 1 886 | Warrants (right to buy) |
2023-12-21 | Rombotis Spiro George | Buy | 6 070 | Common Stock |
2023-12-21 | Rombotis Spiro George | Buy | 6 070 | Warrants (right to buy) |
2023-06-30 | Rombotis Spiro George | Buy | 110 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 94 transactions |
Buy: 4 220 559 | Sell: 12 |
Cyclacel Pharmaceuticals Correlación
10 Correlaciones Más Positivas | |
---|---|
ALSA | 0.919 |
LCAA | 0.913 |
XFIN | 0.908 |
ALXN | 0.905 |
IQ | 0.905 |
PLYA | 0.904 |
JUGG | 0.902 |
IVCP | 0.901 |
VPCB | 0.901 |
TIOAU | 0.9 |
10 Correlaciones Más Negativas | |
---|---|
SIDU | -0.91 |
MTP | -0.902 |
JAGX | -0.902 |
EVLO | -0.892 |
ENNV | -0.89 |
PROC | -0.889 |
DBGI | -0.885 |
LGMK | -0.885 |
TRMK | -0.883 |
SLNG | -0.879 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Cyclacel Pharmaceuticals Finanzas
Annual | 2023 |
Ingresos: | $420 000 |
Beneficio Bruto: | $389 000 (92.62 %) |
EPS: | $-26.51 |
FY | 2023 |
Ingresos: | $420 000 |
Beneficio Bruto: | $389 000 (92.62 %) |
EPS: | $-26.51 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $-32 000.00 (0.00 %) |
EPS: | $-32.23 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-9.93 |
Financial Reports:
No articles found.
Cyclacel Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.150 | 2006-01-18 |
Last Dividend | $0.150 | 2024-01-19 |
Next Dividend | $0 | N/A |
Payout Date | 2024-02-01 | |
Next Payout Date | N/A | |
# dividends | 59 | -- |
Total Paid Out | $8.85 | -- |
Avg. Dividend % Per Year | 5.36% | -- |
Score | 4.27 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 5.00 | |
Div. Directional Score | 0.127 | -- |
Year | Amount | Yield |
---|---|---|
2006 | $0.600 | 14.50% |
2007 | $0.600 | 11.20% |
2008 | $0.600 | 12.60% |
2009 | $0.150 | 7.89% |
2010 | $0 | 0.00% |
2011 | $0.300 | 7.71% |
2012 | $0 | 0.00% |
2013 | $0.600 | 6.67% |
2014 | $0.750 | 8.13% |
2015 | $0.450 | 6.96% |
2016 | $0.600 | 15.30% |
2017 | $0.600 | 9.68% |
2018 | $0.600 | 9.16% |
2019 | $0.600 | 9.60% |
2020 | $0.450 | 9.00% |
2021 | $0.600 | 8.53% |
2022 | $0.600 | 9.68% |
2023 | $0.600 | 5.19% |
2024 | $0.150 | 0.91% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -53.86 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -2.57 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -3.10 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | -0.00889 | -1.000 | -0.0889 | 0.0889 | [0 - 1] |
currentRatioTTM | 0.912 | 0.800 | -0.439 | -0.351 | [1 - 3] |
quickRatioTTM | 0.773 | 0.800 | -0.157 | -0.126 | [0.8 - 2.5] |
cashRatioTTM | 0.414 | 1.500 | 8.81 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00420 | -1.500 | 9.93 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | -18.87 | 2.00 | -6.29 | -10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -18.87 | 2.00 | -9.44 | -10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0610 | -1.500 | 9.76 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.0580 | 1.000 | -2.37 | -2.37 | [0.2 - 0.8] |
operatingProfitMarginTTM | -61.55 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -435.46 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0477 | 0.800 | -3.02 | -2.41 | [0.5 - 2] |
Total Score | -4.75 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.0800 | 1.000 | -0.109 | 0 | [1 - 100] |
returnOnEquityTTM | -3.10 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -18.87 | 2.00 | -6.29 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -18.87 | 2.00 | -6.29 | -10.00 | [0 - 30] |
payoutRatioTTM | -0.00889 | 1.500 | -0.0889 | 0.0889 | [0 - 1] |
pegRatioTTM | -0.00282 | 1.500 | -3.35 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -38.36 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -4.53 |
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico